Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Grekova E V
St.Petersburg State Pediatric Medical University, Russia
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
IFN-�±2b + PUVA for mycosis fungoides (MF) has been described in only few small studies. The aim of our survey was to evaluate the efficacy and tolerability of PUVA + IFN-�±2b therapy for patients with MF. We observed 15 patients with MF. The diagnoses were verified with histological, immunohictochemical methods and molecular analysis. In addition, the safety and tolerability of IFN-�± and PUVA-therapy were evaluated. In terms of the stage of the disease, patients were distributed as follows: IB â�� 1 (7%), IIA â�� 4 (27%), IIB â�� 4 (27%), IIIA â�� 2 (12,5%), IIIB â�� 1 (7%), IVA â�� 1 (7%), IVB â�� 2 (12,5%). PUVA-therapy was performed four times a week with the initial dose of the irradiation was 0,5-1,0 J/cm2. The course of therapy consisted of 39�±7 procedures. The total dose was 159�±43 J/cm2. Also IFN-�± was prescribed to the patients (3 IU three times a week). The total dose was 109�±36 IU. After the therapy, 11 (73%) patients with stage IB-IIIA witnessed mSWAT index reduction of 90-100%, which corresponded to complete clinical remission manifested in the disappearance of cutaneous manifestations and subjective perceptions. 3 (20%) of patients with stage IIIB-IVA saw mSWAT index decreasing from 50 to 75% and 1 (7%) patient with stage IVB of MF did not experience an effect of the therapy. IFN-�±2b + PUVA treatment seemed to be an efficacious and tolerated therapy option for MF patients refractory to PUVA, especially in patients with IB-IIB stage.
E-mail: grekova_kate@mail.ru